Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.37 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.32 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | ITGAL | P20701 | 1/20 | 0.32 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8339815 | 0.81 | POLB (0.47) | LMNAMAPTSMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL3928537 | 0.80 | P2RX4 (0.36) | LTA4HP2RX4LMNAMAPTSMN1; SMN2 | |
| SCHEMBL6159693 | 0.80 | P2RX4 (0.36) | LTA4HP2RX4LMNAMAPTSMN1; SMN2 | |
| SCHEMBL28943133 | 0.78 | CYP2D6 (0.39) | LTA4HP2RX4LMNAMAPTSMN1; SMN2 | |
| SCHEMBL11001435 | 0.77 | LTA4H (0.37) | LTA4HLMNAMAPTSMN1; SMN2NPSR1 | |
| SCHEMBL19121185 | 0.75 | NISCH (0.49) | LMNASMN1; SMN2CA2NISCH | |
| SCHEMBL13614456 | 0.75 | TAAR1 (0.39) | LTA4HLMNAMAPTSMN1; SMN2NPSR1 | |
| SCHEMBL18161457 | 0.73 | LMNA (0.36) | LMNAALDH1A1 | |
| SCHEMBL4553784 | 0.73 | P2RX4 (0.40) | P2RX4LMNAMAPTSMN1; SMN2NPSR1 | |
| SCHEMBL25465449 | 0.72 | CA2 (0.35) | ALDH1A1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104628910-B | Catalyst for producing polypropylene with high isotacticity and preparation method thereof | 中国石油天然气股份有限公司 | 2017-02-08 | — | — | CN | claimed |
| CN-104628910-A | Catalyst for producing polypropylene with high isotacticity and preparation method thereof | PETROCHINA CO LTD | 2015-05-20 | — | — | CN | claimed |
| EP-0001486-B1 | PROCESS FOR PREPARING 2,3-DIHYDRO-2,2-DIMETHYL-7-BENZOFURANOL AND BENZODIOXOLE INTERMEDIATE THEREFOR | FMC Corporation (US) | 1982-05-05 | — | — | EP | claimed |
| EP-0001486-A2 | Process for preparing 2,3-dihydro-2,2-dimethyl-7-benzofuranol and benzodioxole intermediate therefor | FMC Corporation (US) | 1979-04-18 | — | — | EP | claimed |
| US-4118400-A | THERMAL REARRANGEMENT OF 2-ISOPROPYL-1.3-BENZODIOXOLE, ACID CATALYST | FMC CORPORATION (US) | 1978-10-03 | — | — | US | claimed |
| JP-58183682-A | — | — | None | — | — | JP | disclosed |
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | REMIX THERAPEUTICS INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-01-18 | — | — | US | disclosed |
| US-20230365526-A1 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023104111-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) | 2023-06-15 | — | — | WO | disclosed |
| US-20230167093-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-4639536-A | Intermediate, its synthesis, and its use in a process for the preparation of 2,3-dihydro-2,2-dimethyl-7-hydroxybenzofuran | UNION CARBIDE CORPORATION (US) | 1987-01-27 | — | — | US | disclosed |
| US-4562266-A | Process for the preparation of 2,3-dihydro-2,2-dimethyl-7-benzofuranol | ENICHIMICA SECONDARIA, S.P.A. (IT) | 1985-12-31 | — | — | US | disclosed |
| US-4540800-A | FROM CATECHOL, ALDEHYDE OR ALLYL ALCOHOL, SOLID ACID CATALYST | UBE INDUSTRIES, LTD. (JP) | 1985-09-10 | — | — | US | disclosed |
| EP-0123357-A2 | Process for the preparation of 2,3-bihydro-2,2-dimethyl-7-benzofuranol | ENICHIMICA SECONDARIA S.p.A. (IT) | 1984-10-31 | — | — | EP | disclosed |
| JP-S58183682-A | PREPARATION OF 2,3-DIHYDRO-2-METHYL-2,3-DIALKYL-7- HYDROXYBENZOFURAN | UBE IND LTD | 1983-10-26 | — | — | JP | disclosed |
| EP-0001486-B1 | PROCESS FOR PREPARING 2,3-DIHYDRO-2,2-DIMETHYL-7-BENZOFURANOL AND BENZODIOXOLE INTERMEDIATE THEREFOR | FMC Corporation (US) | 1982-05-05 | — | — | EP | disclosed |
| EP-0001486-A2 | Process for preparing 2,3-dihydro-2,2-dimethyl-7-benzofuranol and benzodioxole intermediate therefor | FMC Corporation (US) | 1979-04-18 | — | — | EP | disclosed |
| US-4118400-A | THERMAL REARRANGEMENT OF 2-ISOPROPYL-1.3-BENZODIOXOLE, ACID CATALYST | FMC CORPORATION (US) | 1978-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | RBM17, HNRNPA1, HNRNPAB | LTA4H 3280/4885P2RX4 3921/4885LMNA 304/4885 |
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | LTA4H 3539/4885P2RX4 3606/4885LMNA 3406/4885 |
| US-20230167093-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | LTA4H 2905/4885P2RX4 3895/4885LMNA 324/4885 |
| US-20230365526-A1 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | SNRPA, RBM17, SNRPB2 | LTA4H 3403/4885P2RX4 2638/4885LMNA 214/4885 |
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | HNRNPAB, HNRNPC, HNRNPA1 | LTA4H 1530/4885P2RX4 1624/4885LMNA 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.